One growth share I’d buy today, and one I’d sell

Here’s a growth share that looks too cheap, and one that might just be too expensive.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I love a set of results that’s headlined “A Year of Strong Growth and Development“, and that’s what DCC (LSE: DCC) is saying about its results published Tuesday.

It operates in sales, marketing, distribution and other business services, plying its trade in the energy, technology and healthcare sectors. And all of its divisions have “recorded strong profit growth” in the year.

A bumper year

We saw operating profit up 21%, with adjusted earnings per share up 18%, driven by the firm’s energy division’s outstanding profit rise of 24%. Free cash flow is up by a massive 43%. The dividend was boosted by 15%, though the yield stands at only a modest 1.6%.

For me, DCC looks very attractive on the long-term growth front, with chief executive Tommy Breen predicting another year of profit rises ahead.

As well as organic growth, DCC is active on the acquisition front and is expanding globally, ambitiously snapping up Esso’s retail network in Norway and Shell’s LPG business in Hong Kong and Macau. These overshadow the disposal of its environmental division (for an enterprise value of £219m), and should help it focus on more profitable businesses.

Its recent track record is impressive, with earnings per share growing by 67% in just four years, and we have growth in excess of 10% per year forecast for this year and next.

As I write, the shares are down 3% at 7,135p. That gives us a P/E of a little under 20 on 2019 forecasts, which might put some people off. But for me that’s a fair valuation for a company with the growth potential that I’m seeing here. 

Heading for the cliff?

First Derivatives (LSE: FDP), a firm supplying IT services to the financial sector, also filed an impressive set of results on Tuesday.

Adjusted pre-tax profit came in 24% ahead with adjusted EPS up 19%, and the dividend was lifted by 18% (albeit for a yield of only 0.8%). Net debt looks modest at £13.5m.

With its software subscription model, First Derivatives has good visibility, and says the current year is off to “an encouraging start“, with chairman Seamus Keating saying “we anticipate another year of strong growth“. Its software does seem to be going places, with an increasing number of companies taking it up.

Sky-high shares

If you’re looking for a share price that has soared, look no further — First Derivatives shares are up more than 400% in the past five years, to 2,560p. But the problem for me is that earnings, while appreciating impressively, haven’t kept growing at the same rate. That’s led to a steadily ballooning P/E — forecasts put the shares on a multiple of 45 for the coming year, and that makes me more than a bit twitchy.

I’ve been following growth shares for years, and there’s a common pattern where great results keep rolling in, investors keep on buying the shares, and the price gets unsustainably ahead of rationality. What usually happens is that one set of results comes in perhaps a little below expectations, and the result is a panic sell-off. 

And I see a distinct possibility of that happening here. I’m convinced that First Derivatives is a solid growth company with a very attractive future. But for me, the current share price is just too high.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »